Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-33

Excellent news! We have been waiting to hear about the extra Her-vaxx trials. This one makes huge sense. What I said over the weekend about a possible future trial of Her-vaxx with PD1-vaxx holds true for this trial:

Avelumab is a PD-L1 Checkpoint Inhibitor. It's purpose is to stop the mechanism which the cancer uses to "turn off" the patient's immune response. The purpose of Her-vaxx is to help ensure that the body can generate a more effective immune response targeting the HER2 receptor. In effect, Avelumab would "unleash the dogs" and Her-vaxx would create a better stronger fiercer attack dog to destroy the cancer.

We know that LC has been busting to try Her-vaxx with a current "in market" T-cell MAB. If this works, we can reasonably expect that it would also give improved results in combo with, for example, Keytruda - the really "big name" in Checkpoint Inhibitors.

Now we have positive proof that Big Pharma is looking at Imugene and negotiating with them. Merck is a great start!

There are at least two more studies planned for Her-vaxx, and one of those was described as an "Investigator Sponsored Study." I think we have more exciting news to come...

Cheers

Dave